

22/10/200411:05Print selected from Online session

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.13	5.34

FILE 'CAPLUS' ENTERED AT 11:02:52 ON 22 OCT 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2004 VOL 141 ISS 17  
FILE LAST UPDATED: 20 Oct 2004 (20041020/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> lactoferrin and (il-1 or TNF) and ("scar tissue" or "adhesion formation")  
4183 LACTOFERRIN  
3697 LACTOFERRINS  
4723 LACTOFERRIN  
(LACTOFERRIN OR LACTOFERRINS)  
97825 IL  
809 ILS  
98423 IL  
(IL OR ILS)  
8049658 1  
29636 IL-1  
(IL(W)1)  
50777 TNF  
107 TNFS  
50784 TNF  
(TNF OR TNFS)  
4991 "SCAR"  
1574 "SCARS"  
5998 "SCAR"  
( "SCAR" OR "SCARS")  
615443 "TISSUE"  
303437 "TISSUES"  
786044 "TISSUE"  
( "TISSUE" OR "TISSUES")  
742 "SCAR TISSUE"  
( "SCAR" (W) "TISSUE")  
243886 "ADHESION"  
3394 "ADHESIONS"  
244910 "ADHESION"  
( "ADHESION" OR "ADHESIONS")  
2501537 "FORMATION"  
51626 "FORMATIONS"

2530657 "FORMATION"

("FORMATION" OR "FORMATIONS")

629 "ADHESION FORMATION"

("ADHESION"(W)"FORMATION")

L3 1 LACTOFERRIN AND (IL-1 OR TNF) AND ("SCAR TISSUE" OR "ADHESION  
FORMATION")

=> d ti

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Cytokine inhibitors for use in healing of wounds

=> D ab bib 1

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
AB The author discloses the use of inhibitors a pro-inflammatory cytokine,  
such as **TNF** or **IL-1**, for improving wound  
healing. In one example, the administration of infliximab following  
laminectomy of the sacral vertebrae was shown to limit scaring and  
**adhesion formation.**

AN 2003:719248 CAPLUS

DN 139:244721

TI Cytokine inhibitors for use in healing of wounds

IN Olmarker, Kjell

PA Pharmasurgics AB, Swed.; Orthopaedic Research and Development in Gothe

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003073981	A2	20030912	WO 2003-SE347	20030304
	WO 2003073981	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,				
	RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,				
	NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,				
	GW, ML, MR, NE, SN, TD, TG				
	US 2003176332	A1	20030918	US 2002-92919	20020308
PRAI	SE 2002-667	A	20020305		
	US 2002-92919	A	20020308		

=> file uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

18.74

24.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.70

-0.70

22/10/200411:05Print selected from Online session

FILE 'USPATFULL' ENTERED AT 11:04:48 ON 22 OCT 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 21 Oct 2004 (20041021/PD)  
FILE LAST UPDATED: 21 Oct 2004 (20041021/ED)  
HIGHEST GRANTED PATENT NUMBER: US6807678  
HIGHEST APPLICATION PUBLICATION NUMBER: US2004210975  
CA INDEXING IS CURRENT THROUGH 21 Oct 2004 (20041021/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 21 Oct 2004 (20041021/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2004  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2004

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

```
=> lactoferrin and (il-1 or TNF)  and ("scar tissue" or "adhesion formation")
    1647 LACTOFERRIN
    93 LACTOFERRINS
    1661 LACTOFERRIN
        (LACTOFERRIN OR LACTOFERRINS)
    46490 IL
    2305 ILS
    48250 IL
        (IL OR ILS)
3931301 1
    14395 IL-1
        (IL(W)1)
    20713 TNF
    470 TNFS
    20753 TNF
        (TNF OR TNFS)
    11463 "SCAR"
    5730 "SCARS"
    15113 "SCAR"
        ("SCAR" OR "SCARS")
    231743 "TISSUE"
    130947 "TISSUES"
    254881 "TISSUE"
```

("TISSUE" OR "TISSUES")  
      5150 "SCAR TISSUE"  
          ("SCAR" (W) "TISSUE")  
219299 "ADHESION"  
      5494 "ADHESIONS"  
221278 "ADHESION"  
          ("ADHESION" OR "ADHESIONS")  
841965 "FORMATION"  
      47698 "FORMATIONS"  
854723 "FORMATION"  
          ("FORMATION" OR "FORMATIONS")  
      645 "ADHESION FORMATION"  
          ("ADHESION" (W) "FORMATION")  
L4      18 LACTOFERRIN AND (IL-1 OR TNF) AND ("SCAR TISSUE" OR "ADHESION  
          FORMATION")

=> d ti 1-18

L4      ANSWER 1 OF 18  USPATFULL on STN  
TI      Lactoferrin as an agent in the prevention of organ transplant  
          rejection and graft-versus-host-disease  
  
L4      ANSWER 2 OF 18  USPATFULL on STN  
TI      Methods and compositions using compounds from fetal cells and tissues to  
          improve condition of skin  
  
L4      ANSWER 3 OF 18  USPATFULL on STN  
TI      90 human secreted proteins  
  
L4      ANSWER 4 OF 18  USPATFULL on STN  
TI      Nucleic acids, proteins, and antibodies  
  
L4      ANSWER 5 OF 18  USPATFULL on STN  
TI      Nucleic acids, proteins, and antibodies  
  
L4      ANSWER 6 OF 18  USPATFULL on STN  
TI      Nucleic acids, proteins, and antibodies  
  
L4      ANSWER 7 OF 18  USPATFULL on STN  
TI      Amniotic membrane mediated delivery of bioactive molecules  
  
L4      ANSWER 8 OF 18  USPATFULL on STN  
TI      Novel use of cytokine inhibitors  
  
L4      ANSWER 9 OF 18  USPATFULL on STN  
TI      Transferrin polynucleotides, polypeptides, and antibodies  
  
L4      ANSWER 10 OF 18  USPATFULL on STN  
TI      Colon and colon cancer associated polynucleotides and polypeptides  
  
L4      ANSWER 11 OF 18  USPATFULL on STN  
TI      Nucleic acids, proteins, and antibodies  
  
L4      ANSWER 12 OF 18  USPATFULL on STN  
TI      90 human secreted proteins  
  
L4      ANSWER 13 OF 18  USPATFULL on STN  
TI      Nucleic acids, proteins, and antibodies

L4 ANSWER 14 OF 18 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies

L4 ANSWER 15 OF 18 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies

L4 ANSWER 16 OF 18 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies

L4 ANSWER 17 OF 18 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies

L4 ANSWER 18 OF 18 USPATFULL on STN  
TI Transferrin polynucleotides, polypeptides, and antibodies

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:57:14 ON 22 OCT 2004

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ....' ENTERED AT 10:57:29 ON 22 OCT 2004

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> lactoferrin and il-1 and "scar tissue"

15 FILES SEARCHED...

27 FILES SEARCHED...

40 FILES SEARCHED...

1 FILE IFIPAT

55 FILES SEARCHED...

18 FILE USPATFULL

1 FILE USPAT2

71 FILES SEARCHED...

73 FILES SEARCHED...

3 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L1 QUE LACTOFERRIN AND IL-1 AND "SCAR TISSUE"

=> lactoferrin and (il-1 or TNF) and ("scar tissue" or "adhesion formation")

15 FILES SEARCHED...

1 FILE CAPLUS

27 FILES SEARCHED...

39 FILES SEARCHED...

1 FILE IFIPAT

55 FILES SEARCHED...

18 FILE USPATFULL

1 FILE USPAT2

70 FILES SEARCHED...

4 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L2 QUE LACTOFERRIN AND (IL-1 OR TNF) AND ("SCAR TISSUE" OR "ADHESION FORMATION")

=> file caplus

22/10/200414:36Print selected from Online session

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653rbm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,  
resulting in a closer connection to BABS  
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display  
fields  
NEWS 5 AUG 02 CAPLUS and CA patent records enhanced with European and Japan  
Patent Office Classifications  
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!  
(Version 7.01 for Windows) now available  
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage  
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal  
status data from INPADOC  
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 12 SEP 27 STANDARDS will no longer be available on STN  
NEWS 13 SEP 27 SWETSCAN will no longer be available on STN  
  
NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:27:00 ON 22 OCT 2004

=> index bioscience

22/10/200414:36Print selected from Online session

'BIOSCIGENCE' IS NOT A VALID FILE NAME  
ENTER A FILE NAME OR (IGNORE):bioscience  
'BIOSCIENSE' IS NOT A VALID FILE NAME  
ENTER A FILE NAME OR (IGNORE):bioscience  
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,  
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,  
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,  
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:27:49 ON 22 OCT 2004

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view  
search error messages that display as 0\* with SET DETAIL OFF.

=> lactoferrin p "wound healing"  
27 FILES SEARCHED...  
52 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L1 QUE LACTOFERRIN P "WOUND HEALING"

=> lactoferrin

63	FILE ADISCTI
4	FILE ADISINSIGHT
5	FILE ADISNEWS
463	FILE AGRICOLA
64	FILE ANABSTR
5	FILE ANTE
23	FILE AQUASCI
214	FILE BIOBUSINESS
86	FILE BIOCOMMERCE
167	FILE BIOENG
5042	FILE BIOSIS
210	FILE BIOTECHABS
210	FILE BIOTECHDS
1502	FILE BIOTECHNO
2086	FILE CABA
824	FILE CANCERLIT
4723	FILE CAPLUS
56	FILE CEABA-VTB
8	FILE CEN
69	FILE CIN
145	FILE CONFSCI
4	FILE CROPU
50	FILE DDFB
306	FILE DDFU
1779	FILE DGENE
161	FILE DISSABS
50	FILE DRUGB
1	FILE DRUGMONOG2
373	FILE DRUGU
38	FILE EMBAL
3867	FILE EMBASE



1362	FILE	ESBIOBASE
76	FILE	FEDRIP
4	FILE	FOMAD
4	FILE	FOREGE
607	FILE	FROSTI
413	FILE	FSTA
362	FILE	GENBANK
4	FILE	HEALSAFE
324	FILE	IFIPAT
16	FILE	IMSDRUGNEWS
3	FILE	IMSPRODUCT
5	FILE	IMSRESEARCH
617	FILE	JICST-EPLUS
7	FILE	KOSMET
1091	FILE	LIFESCI
1	FILE	MEDICONF
4337	FILE	MEDLINE
4	FILE	NIOSHTIC
14	FILE	NTIS
13	FILE	NUTRACEUT
8	FILE	OCEAN
1854	FILE	PASCAL
7	FILE	PHAR
57 FILES SEARCHED...		
12	FILE	PHARMAML
88	FILE	PHIN
379	FILE	PROMT
7	FILE	PROUSDDR
1	FILE	RDISCLOSURE
4322	FILE	SCISEARCH
1675	FILE	TOXCENTER
1661	FILE	USPATFULL
117	FILE	USPAT2
5	FILE	VETB
56	FILE	VETU
1	FILE	WATER
624	FILE	WPIDS
2	FILE	WPIFV
624	FILE	WPINDEX

69 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L2 QUE LACTOFERRIN

=> lactoferrin and "wound healing"

1	FILE	ADISINSIGHT
4	FILE	BIOSIS
2	FILE	BIOTECHABS
2	FILE	BIOTECHDS
3	FILE	BIOTECHNO
1	FILE	CABA
3	FILE	CANCERLIT
21	FILE	CAPLUS
53	FILE	DGENE
8	FILE	EMBASE
2	FILE	ESBIOBASE
2	FILE	FEDRIP
1	FILE	FROSTI
1	FILE	FSTA

22/10/200414:36Print selected from Online session

40 FILES SEARCHED...

8	FILE IFIPAT
5	FILE IMSDRUGNEWS
1	FILE IMSRESEARCH
1	FILE JICST-EPLUS
7	FILE MEDLINE
1	FILE PHAR
4	FILE PHIN
13	FILE PROMT
1	FILE PROUSDDR
7	FILE SCISEARCH
7	FILE TOXCENTER
175	FILE USPATFULL
9	FILE USPAT2
10	FILE WPIDS
10	FILE WPINDEX

29 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L3 QUE LACTOFERRIN AND "WOUND HEALING"

=> file caplus biosis medline biotechno  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.42	3.63

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:31:21 ON 22 OCT 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:31:21 ON 22 OCT 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'MEDLINE' ENTERED AT 14:31:21 ON 22 OCT 2004

FILE 'BIOTECHNO' ENTERED AT 14:31:21 ON 22 OCT 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

=> lactoferrin and "wound healing"

L4 35 LACTOFERRIN AND "WOUND HEALING"

=> dup remove

ENTER L# LIST OR (END):l4

PROCESSING COMPLETED FOR L4

L5 29 DUP REMOVE L4 (6 DUPLICATES REMOVED)

=> d ti 1-15

L5 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Interleukin 23 agonists and antagonists for treating and improving  
wound healing

L5 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Lactoferrin compositions and methods of wound treatment

L5 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Formulations for topical delivery of bioactive substances and methods for  
their use

- L5 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Technology evaluation: rh **lactoferrin**, Agennix
- L5 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Cytokine inhibitors for use in healing of wounds
- L5 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Immobilized recombinant humanized **lactoferrin** with low allergenicity as antimicrobial agent for human tissue applications and food processing
- L5 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Amniotic membrane-mediated delivery of bioactive molecules
- L5 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Growth-promoting agent for treatment of surface wounds and gastrointestinal injuries and diseases and ulcers.
- L5 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
TI Low Density Lipoprotein Receptor-related Protein (LRP) Is Required for **Lactoferrin**-enhanced Collagen Gel Contractile Activity of Human Fibroblasts
- L5 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Antibacterial, antioxidant, immunomodulating and anticarcinogenic preparation and a method for using it
- L5 ANSWER 11 OF 29 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
TI Analysis of Rabbit Tear Proteins by High Pressure Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (LC-ESI-MS).
- L5 ANSWER 12 OF 29 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN  
TI Comment on: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study [1] (multiple letters)
- L5 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Systems for oral delivery
- L5 ANSWER 14 OF 29 MEDLINE on STN  
TI The inflammatory response following treatment of abdominal aortic aneurysms: a comparison between open surgery and endovascular repair.
- L5 ANSWER 15 OF 29 MEDLINE on STN  
TI **Lactoferrin** protects against UV-B irradiation-induced corneal epithelial damage in rats.
- => d ti 16-29
- L5 ANSWER 16 OF 29 MEDLINE on STN  
TI Dry eye and closed eye tears.
- L5 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2  
TI Evaluation of bovine **lactoferrin** as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster

- L5 ANSWER 18 OF 29 MEDLINE on STN  
TI [Components of antibacterial and fibrinolytic activity of human saliva in normal and disordered **wound healing**].  
Komponenten der antibakteriellen und der fibrinolytischen Aktivität des menschlichen Gesamtspeichels bei normaler und gestörter Wundheilung.
- L5 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Desiccant emulsion comprising kaolin and titanium dioxide for the skin
- L5 ANSWER 20 OF 29 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
TI Estrogen, growth factors, and carcinogenesis of the reproductive tract.
- L5 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Estrogen, growth factors, and carcinogenesis of the reproductive tract
- L5 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Methods of enhancing repair, healing and augmentation of bone implants
- L5 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3  
TI **Lactoferrin** as a suppressor of cell migration of gastrointestinal cell lines
- L5 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Agents for binding to advanced glycosylation end-products, and methods of their use
- L5 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Pharmaceutical compositions containing peptides for **wound healing**
- L5 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI **Wound healing** promoters, skin cosmetics or hair tonics containing **lactoferrins** and epidermal growth factor
- L5 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Inhibition of extracellular matrix and serum protein binding to *Staphylococcus aureus* by heparin and various polysulfated agents
- L5 ANSWER 28 OF 29 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN  
TI Transforming growth factors  $\beta 1$ ,  $\beta 2$ , and  $\beta 3$  messenger RNA and protein expression in mouse uterus and vagina during estrogen-induced growth: A comparison to other estrogen-regulated genes
- L5 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
TI Cell growth-promoting agents from a milk product extract for animal tissue culture and pharmaceutical and veterinary uses

=> d ab bib 1,2, 4, 5, 6, 25

- L5 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
AB Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper **wound healing**. Provided are methods of using of a anti-IL-23 or IL23 receptor antibody, antisense nucleic acid, interference RNA or cytokine mol.
- AN 2004:566551 CAPLUS  
DN 141:122335

TI Interleukin 23 agonists and antagonists for treating and improving  
wound healing

IN Bowman, Edward P.; Chen, Shi-juan; Cua, Daniel J.

PA Schering Corporation, USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058178	A2	20040715	WO 2003-US40937	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-436274P	P	20021223		

L5 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN

AB The present invention relates to **lactoferrin** compns. and methods of using the compns. to treat wounds. The compns. can be administered alone or in combination with other standard **wound healing** therapies. **Lactoferrin** enhances the local immune system and kills bacteria infecting the wound. For example, a recombinant human **lactoferrin** (rhLF) gel formulation containing 0.1% to 8.5% rhLF comprised phosphate buffer with rhLF 86.67%, Carbopol 980 1.0%, disodium edetate 0.1%, phenoxyethanol 1.0%, glycerin 4.0%, propylene glycol 5.0%, dimethicone 0.4%, citric acid 0.0956%, 20% NaOH as needed to pH 6.5-7.5, and water to 100%. RhLF gels ranging from 0.1% to 8.5% mediated an improvement in the incidence of 75% wound closure of 77% in normal mice at day 12 (p<0.01) and of 66% in diabetic db/db mice at day 15 (p<0.05).

AN 2004:252366 CAPLUS

DN 140:276199

TI **Lactoferrin** compositions and methods of wound treatment

IN Engelmayer, Jose; Varadhachary, Atul

PA Agennix Incorporated, USA

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024180	A1	20040325	WO 2003-US29069	20030916
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,  
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
 GW, ML, MR, NE, SN, TD, TG

US 2004142037 A1 20040722 US 2003-663258 20030916  
 PRAI US 2002-410981P P 20020916  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
 AB A review. Agennix is developing recombinant human (rh)  
**lactoferrin**, a glycoprotein with antibiotic, anti-inflammatory and  
 immunomodulatory activity, for the potential treatment of cancers, asthma  
 and chronic wounds. Rh **Lactoferrin** is currently undergoing  
 phase II clin. trials.  
 AN 2004:640494 CAPLUS  
 TI Technology evaluation: rh **lactoferrin**, Agennix  
 AU Andersen, Jeanette H.  
 CS Department of Medical Microbiology, University Hospital of North Norway,  
 Tromsø, N-9038, Norway  
 SO Current Opinion in Molecular Therapeutics (2004), 6(3), 344-349  
 CODEN: CUOTFO; ISSN: 1464-8431  
 PB Thomson Current Drugs  
 DT Journal; General Review  
 LA English

L5 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN  
 AB The author discloses the use of inhibitors a pro-inflammatory cytokine,  
 such as TNF or IL-1, for improving **wound healing**. In  
 one example, the administration of infliximab following laminectomy of the  
 sacral vertebrae was shown to limit scarring and adhesion formation.  
 AN 2003:719248 CAPLUS  
 DN 139:244721  
 TI Cytokine inhibitors for use in healing of wounds  
 IN Olmarker, Kjell  
 PA Pharmasurgics AB, Swed.; Orthopaedic Research and Development in Gothe  
 SO PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003073981	A2	20030912	WO 2003-SE347	20030304
WO 2003073981	A3	20031127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003176332	A1	20030918	US 2002-92919	20020308
PRAI SE 2002-667	A	20020305		
US 2002-92919	A	20020308		

L5 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN

AB This invention relates to immobilized recombinant humanized **lactoferrin** (IRHL) and to the use thereof in the reduction of microbial contamination of substances while avoiding the risk of cow's milk allergy (CMA) associated with native bovine milk-derived **lactoferrin** or immobilized native bovine milk-derived **lactoferrin**. The preferred form of recombinant humanized **lactoferrin** is recombinant human **lactoferrin**, but **lactoferrins** from other mammals (like apes) can also be used. Recombinant humanized **lactoferrin** is defined as a form of **lactoferrin** that has an amino acid sequence that is more than 99% homologous to human **lactoferrin** (as determined using BLAST). IRHL can be applied to human tissues, including oral mucosoidal lining tissue, gastrointestinal epithelial lining tissue, or skin epidermal lining tissue or the collagen tissues. Specific embodiments include oral care formulations, wound care formulations (both external and internal wounds) (such as band aids), and formulations to maintain healthy gastrointestinal tract. The present invention includes the use of IRHL with medicines and drugs taken into the body of a human or other animal, or applied topically. IRHL can also be used in various stages of food processing. IRHL is especially useful in treating whole muscle and ground meat products, including beef products, pork products and poultry products, such as sausages, salamis, hotdogs and the like. It is especially useful in treating food-borne pathogens, food-borne radiation-resistant bacteria, and food spoilage microorganisms.

AN 2003:551529 CAPLUS

DN 139:106492

TI Immobilized recombinant humanized **lactoferrin** with low allergenicity as antimicrobial agent for human tissue applications and food processing

IN Braun, Steven; Van Belzen, Nico; Nimmagudda, Ram

PA Campina B.V., Neth.

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057712	A2	20030717	WO 2002-US40838	20021223
	WO 2003057712	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003229011	A1	20031211	US 2002-326269	20021223
PRAI	US 2001-342747P	P	20011228		

L5 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN

AB Pharmaceutical compns. for wound healing contain peptides (**lactoferrin** hydrolyzate) such as Phe-Gln-Trp-Gln-Arg-Asn or their pharmaceutically acceptable derivs. or salts as active ingredients. The peptides can be synthesized or obtained by enzymic

hydrolysis of bovine **lactoferrin**. Tablets were formulated containing Phe-Gln-Trp-Gln-Arg-Asn 10.0, lactose monohydrate 30.0, corn starch 19.8, crystalline cellulose 28.0, magnesium silicate pentahydrate 2.0, and magnesium stearate 0.2 mg.

AN 1996:367654 CAPLUS

DN 125:41764

TI Pharmaceutical compositions containing peptides for **wound healing**

IN Shimamura, Seiichi; Fukuwatari, Yasuo; Takase, Mitsunori; Shinoda, Kazumi; Yamauchi, Koji; Kuwata, Hidefumi; Yamazaki, Natsuko

PA Morinaga Milk Industry Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 08081387	A2	19960326	JP 1994-241894	19940909
PRAI	JP 1994-241894		19940909		